HCW Biologics (HCWB) SVP Flowers Lee Buys 7,736 Shares in Private Placement

What Happened

• Flowers Lee, SVP of Business Development at HCW Biologics (HCWB), purchased 7,736 shares directly from the company in a private placement on July 29, 2026. The shares were bought at $2.58 per share for a total cash outlay of $19,998. This was a purchase (insider acquisition), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction type/code: Purchase (P) — private placement under a Securities Purchase Agreement dated July 29, 2026.
• Transaction date and price: July 29, 2026 — 7,736 shares at $2.58 per share.
• Total value: $19,998.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Footnotes: Shares were purchased directly from the issuer in a transaction exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D. The reporting person is also entitled to receive common warrants exercisable for up to 7,736 shares; issuance of those warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). If issued, the warrants would be immediately exercisable and expire 5.5 years from issuance.
• Filing timeliness: Period of Report 2026-07-29; Form 4 filed 2026-07-31 — filed within the standard two-business-day reporting window (timely).

Context

• This was a direct purchase from the company (private placement), not an open-market trade. The additional common warrants could increase potential future ownership if and when shareholders approve their issuance; until then, the warrants are contingent and not exercisable. The cash amount involved is modest (~$20k), so investors may weigh this as a limited-size insider buy.